Dr. Reddy's Laboratories Ltd.


  • 1m
  • 3m
  • 6m
  • 1y
  • 2y
  • 5y
Apr 26, 2017
Prev close: 2,611.05
Apr 26, 2017
Market cap:
Market cap(USD):
Shares: 165.67M

Currency in INR

Company profile

Market(Ticker): BOM(500124)
Health Technology
Pharmaceuticals: Generic
Full time employees: 22,175

Business summary

Dr. Reddy's Laboratories Ltd. engages in the manufacture and market of pharmaceutical products. It operates through the following segments: Pharmaceutical Services and Active Ingredient; Global Generics; and Proprietary Products. The Pharmaceutical Services and Active Ingredients segments includes active pharmaceutical ingredients and intermediaries also known as active pharmaceutical products or bulk drug; it also provides research services. The Global Generics segment consists of finished pharmaceutical products ready for consumption. The Proprietary Products segment involves the discovery of new chemical entities for subsequent commercialization and out-licensing. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

Company background

Dr. Reddy's Laboratories is a leading Indian generic drugmaker that operates business in more than 20 countries. Founder K. Anji Reddy is among the business leaders who spearheaded the development of India's generic drug industry.

The company was founded in 1984, and its generic drug business found its way to a growth track in 1986. It continues to steadily expand in 2000s. It has made acquisitions and now has development bases in the U.K. and the Netherlands.

Dr. Reddy's Laboratories has been stepping up its biomedicine operations. These include the development of anti-cancer drugs, which the company considers a big source of future earnings. Dr. Reddy's Laboratories aims to reinforce its biomedicine operations through a tie-up with the German drugmaker Merck.

Anji Reddy died in 2013. His son, Satish Reddy, serves as company chairman and his son-in-law as co-chairman. The founding family owns nearly 25% of the company's shares.

In the news

Financial highlights

Mar 2016

  • Local currency
  • US Dollar
Revenue 154,708M
Gross profit 87,272M
Operating income 28,806M
Income before tax 26,911M
Net income 20,013M
EBITDA 39,056M
Diluted EPS 116.99
Dividends per share 20
Total assets 207,650M
Total liabilities 79,314M
Total equity 128,336M
Operating cash flow 41,613M

Currency in INR

Revenue 2,363.00M
Gross profit 1,332.99M
Operating income 439.98M
Income before tax 411.03M
Net income 305.67M
EBITDA 596.54M
Diluted EPS 1.78
Dividends per share 0.30
Total assets 3,135.64M
Total liabilities 1,197.68M
Total equity 1,937.95M
Operating cash flow 635.59M

Currency in USD

Valuation measures

Mar 2016

PER 25.86
ROA 9.94%
ROE 16.70%
Operating margin 18.61%
Profit margin 12.93%

Key executive

  • Co-Chairman, Chief Executive Officer & MD: Gunupati Venkateswara Prasad
  • President, CFO & Global Head-IT: Saumen Chakraborty
  • Chief Operating Officer: Abhijit Mukherjee
  • Secretary & Compliance Officer: Sandeep Poddar
  • EVP, Head-Emerging Markets & Global Generics: M. V. Ramana

Share holders

  • Dr. Reddy's Holdings Ltd.(24.5%)
  • First State Investment Management (UK) Ltd.(6.9%)
  • OppenheimerFunds, Inc.(5.2%)
  • BlackRock Fund Advisors(1.9%)
  • Abu Dhabi Investment Authority (Investment Management)(1.9%)
  • Life Insurance Corp. of India(1.4%)
  • Franklin Templeton Asset Management (India) Pvt Ltd.(1.4%)
  • GIC Pte Ltd. (Investment Management)(1.4%)
  • Vontobel Asset Management, Inc.(1.2%)


  • Website:
  • Address: Door No. 8-2-337, Road No. 3, Hyderabad, 500034, India
  • Phone: +91.40.49002900

Copyright © 2017 FactSet Research Systems Inc. All rights reserved.